Published in Steroids on December 06, 2004
HOP-2A - Intratesticular Hormone Levels (HOP-2A) | NCT00756561
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Steroid hormone analysis by tandem mass spectrometry. Clin Chem (2009) 1.47
Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trial. Fertil Steril (2012) 1.44
Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. J Clin Endocrinol Metab (2010) 1.08
Serum LH correlates highly with intratesticular steroid levels in normal men. J Androl (2009) 0.95
Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods. Steroids (2008) 0.91
Atmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer. Anal Chem (2010) 0.88
Mass spectrometric assay and physiological-pharmacological activity of androgenic neurosteroids. Neurochem Int (2007) 0.86
Accurate determination of tissue steroid hormones, precursors and conjugates in adult male rat. J Biochem (2012) 0.83
The effect of gonadotropin withdrawal and stimulation with human chorionic gonadotropin on intratesticular androstenedione and DHEA in normal men. J Clin Endocrinol Metab (2011) 0.80
Luteinizing hormone, testosterone and inhibin B levels in the peripubertal period and racial/ethnic differences among boys aged 6-11 years: analyses from NHANES III, 1988-1994. Clin Endocrinol (Oxf) (2010) 0.79
Simultaneous quantification of steroids in rat intratesticular fluid by HPLC-isotope dilution tandem mass spectrometry. J Androl (2011) 0.75
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol (2006) 2.35
Cholesterol transport, peripheral benzodiazepine receptor, and steroidogenesis in aging Leydig cells. J Androl (2002) 2.23
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res (2007) 2.07
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol (2007) 2.01
Best practice policies for male infertility. Fertil Steril (2002) 1.88
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood (2013) 1.87
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol (2008) 1.84
In search of rat stem Leydig cells: identification, isolation, and lineage-specific development. Proc Natl Acad Sci U S A (2006) 1.79
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol (2008) 1.71
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Chapter 1: The management of erectile dysfunction: an AUA update. J Urol (2005) 1.55
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res (2004) 1.55
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol (2011) 1.52
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol (2002) 1.52
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther (2002) 1.51
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst (2006) 1.48
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.47
Interaction of imatinib with human organic ion carriers. Clin Cancer Res (2008) 1.47
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther (2007) 1.47
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Ductal access for prevention and therapy of mammary tumors. Cancer Res (2006) 1.38
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst (2006) 1.38
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res (2009) 1.35
Phthalate-induced Leydig cell hyperplasia is associated with multiple endocrine disturbances. Proc Natl Acad Sci U S A (2004) 1.35
Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development. Proc Natl Acad Sci U S A (2011) 1.34
Leydig cells: From stem cells to aging. Mol Cell Endocrinol (2009) 1.32
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol (2008) 1.30
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol (2005) 1.25
Stage-specific gene expression is a fundamental characteristic of rat spermatogenic cells and Sertoli cells. Proc Natl Acad Sci U S A (2008) 1.25
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst (2011) 1.23
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol (2005) 1.22
Best practice policies for male infertility. J Urol (2002) 1.21
Effect of myxothiazol on Leydig cell steroidogenesis: inhibition of luteinizing hormone-mediated testosterone synthesis but stimulation of basal steroidogenesis. Endocrinology (2007) 1.20
Isolation of sertoli cells from adult rat testes: an approach to ex vivo studies of Sertoli cell function. Biol Reprod (2003) 1.19
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab (2005) 1.19
Leydig cell aging and the mechanisms of reduced testosterone synthesis. Mol Cell Endocrinol (2008) 1.18
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.16
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol (2005) 1.16
Gene expression in rat leydig cells during development from the progenitor to adult stage: a cluster analysis. Biol Reprod (2005) 1.15
Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res (2007) 1.12
In utero exposure to di-(2-ethylhexyl) phthalate exerts both short-term and long-lasting suppressive effects on testosterone production in the rat. Biol Reprod (2008) 1.10
Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 1.10
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol (2007) 1.10
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs (2006) 1.08
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. J Pharm Biomed Anal (2006) 1.07
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res (2012) 1.06
Aging and the brown Norway rat leydig cell antioxidant defense system. J Androl (2005) 1.05
The androgen microenvironment of the human testis and hormonal control of spermatogenesis. Ann N Y Acad Sci (2005) 1.04
Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.03
Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS One (2013) 1.03
Essential roles of lipoyl domains in the activated function and control of pyruvate dehydrogenase kinases and phosphatase isoform 1. Eur J Biochem (2003) 1.03
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res (2009) 1.02
Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res (2006) 1.02
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res (2005) 1.01
Identification, proliferation, and differentiation of adult Leydig stem cells. Endocrinology (2012) 1.01
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. Am J Clin Oncol (2006) 1.01
Insight on pathogenesis of varicoceles: relationship of varicocele and body mass index. Urology (2006) 1.00
Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Androl (2004) 1.00
Noninvasive laser vasectomy: preliminary ex vivo tissue studies. Lasers Surg Med (2009) 0.99
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther (2003) 0.99
Vitamin E, aging and Leydig cell steroidogenesis. Exp Gerontol (2005) 0.99
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin Cancer Res (2005) 0.99
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther (2006) 0.99
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther (2008) 0.98
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res (2013) 0.97
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res (2006) 0.97
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther (2004) 0.97
Gestational exposure to atrazine: effects on the postnatal development of male offspring. J Androl (2007) 0.96
Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther (2007) 0.95
Stage-specific changes in GDNF expression by rat Sertoli cells: a possible regulator of the replication and differentiation of stem spermatogonia. Biol Reprod (2011) 0.95
Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.95
Stem Leydig cells: from fetal to aged animals. Birth Defects Res C Embryo Today (2010) 0.95
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res (2003) 0.94
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics (2011) 0.93
The cathepsin L first intron stimulates gene expression in rat sertoli cells. Biol Reprod (2007) 0.93
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. Pharmacotherapy (2004) 0.93
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. Invest New Drugs (2006) 0.93
Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.93
Ontogeny and sorafenib metabolism. Clin Cancer Res (2012) 0.92
Nuclear factor-kappaB activates transcription of the androgen receptor gene in Sertoli cells isolated from testes of adult rats. Endocrinology (2003) 0.92
Age-related decreases in Leydig cell testosterone production are not restored by exposure to LH in vitro. Endocrinology (2002) 0.92
Pyruvate dehydrogenase kinase isoform 2 activity limited and further inhibited by slowing down the rate of dissociation of ADP. Biochemistry (2004) 0.91
Application of an optical clearing agent during noninvasive laser coagulation of the canine vas deferens. J Biomed Opt (2010) 0.91
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin Cancer Res (2012) 0.90
Dibutyryl cyclic adenosine monophosphate restores the ability of aged Leydig cells to produce testosterone at the high levels characteristic of young cells. Endocrinology (2004) 0.90
Oxidative stress and phthalate-induced down-regulation of steroidogenesis in MA-10 Leydig cells. Reprod Toxicol (2013) 0.90
Aging and caloric restriction: effects on Leydig cell steroidogenesis. Exp Gerontol (2005) 0.89
Stem Leydig cell differentiation: gene expression during development of the adult rat population of Leydig cells. Biol Reprod (2011) 0.89
Temporal relationships among testosterone production, steroidogenic acute regulatory protein (StAR), and P450 side-chain cleavage enzyme (P450scc) during Leydig cell aging. J Androl (2004) 0.89
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res (2007) 0.89